ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trastuzumab deruxtecan

Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.

Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 13, 201849 company-led studies, 31 open or runningNext primary completion: Feb 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo2611 open or runningphase 3since Apr 13, 2018Sep 21, 2015Oct 1, 2027phase 3 · NCT05950945
AstraZenecaits history only2120 open or runningphase 4since May 21, 2024Sep 22, 2017Feb 10, 2027phase 2 · NCT06271837
Pfizerits history only10 open or runningphase 2since Aug 31, 2020Aug 31, 2020none ahead
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Merck, Parexel, Bristol-Myers Squibb and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 13 earlier studies, Sep 21, 2015 to Jul 8, 2019.

  1. Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
  2. Jul 31, 2019Phase 1 study in Breast NeoplasmsNCT04042701 · 115 enrolled · United States, France, Spain and more
  3. Nov 2, 2020Phase 3 study in HER2-Positive Primary Breast CancerNCT04622319 · 1,600 enrolled · United States, Argentina, Australia and more
  4. Nov 19, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04644237 · 152 enrolled · United States, Australia, Canada and more
  5. Jan 8, 2021Phase 3 study in Stomach NeoplasmsNCT04704934 · 490 enrolled · Argentina, Belgium, Brazil and more
  6. Jan 19, 2021Phase 2 study in Colorectal NeoplasmsNCT04744831 · 122 enrolled · United States, Australia, Belgium and more
  7. May 22, 2023Phase 3 study in Breast NeoplasmsNCT05950945 · 250 planned · United States, Australia, Belgium and more
  8. Dec 8, 2023Phase 3 study in Neoplasm MetastasisNCT06174987 · 75 planned · United States, Australia, Brazil and more
  9. Dec 9, 2024Phase 3 study in Stomach NeoplasmsNCT06731478 · 726 planned · United States, Argentina, Australia and more
  10. Feb 5, 2025Phase 3 study in Ovarian NeoplasmsNCT06819007 · 582 planned · United States, Australia, Austria and more
  11. Mar 21, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06899126 · 686 planned · United States, Argentina, Belgium and more
  12. Jun 3, 2025Phase 1 study in RecurrenceNCT07015697 · 76 planned · United States, Brazil, France and more
  13. Jun 6, 2025Phase 3 study in Endometrial NeoplasmsNCT07022483 · 710 planned · United States, Argentina, Chile and more
  14. Jun 25, 2026Phase 3 study in Breast NeoplasmsNCT07683754 · 200 planned · United States
  15. Oct 26, 2026Primary completion moved from 2026-08-03 to 2028-02-17Date moved laterphase 3 · +18 months · NCT06174987

Ahead

  1. Oct 1, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05950945
  2. Feb 17, 2028Primary completion: phase 3 study in Neoplasm MetastasisNCT06174987
  3. Jun 1, 2028Primary completion: phase 3 study in Stomach NeoplasmsNCT06731478
  4. Nov 1, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT06819007

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 26 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07683754Breast Neoplasms · United States3RecruitingJul 4, 2030200
NCT07022483Endometrial Neoplasms · United States, Argentina, Chile and more3RecruitingFeb 26, 2030710
NCT07015697Recurrence · United States, Brazil, France and more1RecruitingDec 31, 202876
NCT06899126Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3RecruitingApr 24, 2030686
NCT06819007Ovarian Neoplasms · United States, Australia, Austria and more3RecruitingNov 1, 2028582
NCT06731478Stomach Neoplasms · United States, Argentina, Australia and more3RecruitingJun 1, 2028726
NCT06174987Neoplasm Metastasis · United States, Australia, Brazil and more3RecruitingFeb 17, 202875
NCT05950945Breast Neoplasms · United States, Australia, Belgium and more3RecruitingOct 1, 2027250
NCT04744831Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedNov 1, 2022122
NCT04704934Stomach Neoplasms · Argentina, Belgium, Brazil and more3Active, not recruitingAug 31, 2026490
NCT04644237Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedDec 23, 2022152
NCT04622319HER2-Positive Primary Breast Cancer · United States, Argentina, Australia and more3Active, not recruitingJul 2, 20251,600
NCT04042701Breast Neoplasms · United States, France, Spain and more1Active, not recruitingJul 21, 2025115
NCT04014075Neoplasm Metastasis · United States, Belgium, Italy and more2CompletedNov 8, 202179
NCT03734029Breast Neoplasms · United States, Austria, Belgium and more3CompletedJan 11, 2022557
NCT03523572Breast Neoplasms · United States, Belgium, France and more1CompletedJul 22, 202186
NCT03529110Breast Neoplasms · United States, Australia, Belgium and more3CompletedMay 21, 2021524
NCT03523585Breast Neoplasms · United States, Australia, Belgium and more3CompletedJun 30, 2022608
NCT03505710Carcinoma, Non-Small-Cell Lung · United States, France, Japan and more2TerminatedMay 3, 2021181
NCT03384940Colorectal Neoplasms · United States, Italy, Japan and more2CompletedAug 9, 201986
NCT03383692Neoplasm Metastasis · Japan, Korea, Republic of, Taiwan1CompletedSep 26, 201840
NCT03368196Adenocarcinoma · Taiwan1CompletedSep 14, 201812
NCT03366428Breast Neoplasms · Japan1CompletedDec 5, 201851
NCT03329690Gastrointestinal Neoplasms · Japan, Korea, Republic of2CompletedNov 8, 2019233
NCT03248492Breast Neoplasms · United States, Belgium, Canada and more2TerminatedMar 21, 2019253
NCT02564900Neoplasms · United States, Japan1CompletedFeb 1, 2019292

How it is read

Names in the registry

  • “Trastuzumab deruxtecan”, 22 entries
  • “Trastuzumab Deruxtecan”, 10 entries
  • “DS-8201a”, 7 entries
  • “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
  • “T-DXd”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.